Navigation Links
Common Medications Could Cause Physical Impairment in the Elderly
Date:5/3/2008

Drugs for acid reflux, urinary incontinence 'slow down' seniors, studies say

SATURDAY, May 3 (HealthDay News) -- Two new studies show that anticholinergics, a commonly prescribed group of drugs, may cause elderly people to "slow down" in their daily physical activities.

The two reports from researchers at Wake Forest University School of Medicine support findings released a few weeks ago that anticholinergic drugs -- which treat a variety of diseases and conditions, including acid reflux, Parkinson's disease and urinary incontinence -- may cause older people to lose their thinking skills more quickly than those who don't take the medicines.

Anticholinergic drugs work by stopping acetylcholine, a chemical that enhances communication between nerve cells in the brain, from binding to its receptors in nerve cells.

In the first Wake Forest study, older adults taking anticholinergics became more likely to walk more slowly and to need help in other daily activities.

"These results were true even in older adults who have normal memory and thinking abilities," study author Dr. Kaycee M. Sink said in a prepared statement. "For older adults taking a moderately anticholinergic medication, or two or more mildly anticholinergic medications, their function was similar to that of someone three to four years older."

Common anticholinergic medicines cited in the study included the blood pressure medication nifedipine (Adalat or Procardia), the stomach antacid ranitidine (Zantac) and the incontinence medication tolterodine (Detrol).

The findings, which involved more than 3,000 people, average age 78, were scheduled to be presented Saturday at the American Geriatrics Society annual meeting, in Washington, D.C.

In a separate Wake Forest study, published online in April in the Journal of the American Geriatrics Society, Sink found that older nursing home residents who took medicines for dementia along with anticholingerics for incontinence declined in function 50 percent faster than those only treated only for dementia.

"Over a year's time, the decline we observed would represent a resident going from requiring only limited assistance in an activity to being completely dependent, or from requiring only supervision to requiring extensive assistance in an activity," said Sink, an assistant professor of internal medicine-gerontology at Wake Forest.

The seniors in the second study had completed at least two consecutive prescriptions for cholinesterase inhibitors, a family of drugs used to treat dementia by increasing levels of acetylcholine. These include donepezil (brand name Aricept), galantamine (Razadyne), rivastigmine (Exelon) and tacrine (Cognex).

About 10 percent of those studied were also taking either oxybutynin or tolterodine, the two most commonly prescribed drugs for urinary incontinence.

"The two drugs are pharmacological opposites, which led us to hypothesize that the simultaneous treatment of dementia and incontinence could lead to reduced effectiveness of one or both drugs, Sink said.

As an estimated 33 percent of people with dementia also take a medicine to control incontinence, this finding is especially alarming.

The two studies suggest that physicians should carefully consider the implications when prescribing anticholingeric medications to older adults.

More information

The U.S. National Institute on Aging has more about older adults and medications.



-- Kevin McKeever



SOURCE: Wake Forest University School of Medicine, news releases, April 30 and May 3, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Commonly used medications associated with impaired physical function in older adults
2. NHP Declares Its Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
3. Pennsylvania Pharmacy Carve-out Poses Risks for Commonwealths Neediest Citizens and Taxpayers, National Organization Testifies
4. Delusions Common in Pediatric ICU
5. Daily aspirin may reduce risk of common type of breast cancer
6. Kidney Care Community Applauds National Taxpayers Unions Endorsement of Medicare Reforms to Extend Patient Private Health Insurance Coverage; Calls Proposal Common Sense Coverage Reform
7. Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence
8. Common Chemotherapy Drug Linked to Memory Problems
9. Obesity, inactivity as common among cancer survivors as rest of Canadians, study shows
10. Common Medications May Harm Memory in Older People
11. Almost Family Announces Pricing of 2,250,000 Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Medications Could Cause Physical Impairment in the Elderly
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company is ... As a means of expanding capabilities Flottman has added a G&K Vijuk ... code professional inserts (PIs) and patient package inserts (PPIs) that will marry with ...
(Date:12/9/2016)... ... 2016 , ... Mediaplanet today announces distribution of the latest edition of “Transplants,” ... up as an organ donor for the 123,000 people in the United States who ... save up to 8 saves through organ donation and enhance many others through tissue ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest Healthcare ... owned by an affiliate of Seavest, has won a prestigious national healthcare real ... County ambulatory care center (ACC) was named “Best New Development, MOBs and Other ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch ... world headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra ... personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness program ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: